Francisco A. Moreno finds repeated psilocybin doses reduce OCD symptoms in clinical trial
Updated
Updated · PsyPost · Apr 25
Francisco A. Moreno finds repeated psilocybin doses reduce OCD symptoms in clinical trial
9 articles · Updated · PsyPost · Apr 25
In a University of Arizona trial, 15 adults with treatment-resistant OCD received weekly psilocybin or placebo over eight weeks, with 73% showing at least 35% symptom reduction and 40% achieving remission.
The high-dose psilocybin group experienced significant, lasting symptom relief, with benefits persisting for most participants at six months. Treatments were generally safe, with no serious adverse events or psychosis reported.
The study’s small sample size, intensive protocol, and challenges with blinding limit generalizability. Researchers plan larger trials to confirm efficacy and explore mechanisms, aiming to offer alternatives for patients unresponsive to standard therapies.
With new federal support, how soon could psilocybin therapy become a reality for OCD patients?
Could microdosing be a safer, at-home alternative to high-dose clinical OCD treatments?
Will intensive 10-hour sessions make this breakthrough OCD therapy unaffordable for most?
Beyond nausea, what are the hidden psychological risks of using psilocybin to treat severe OCD?
If psilocybin resets rigid brain patterns, could it offer a permanent cure unlike daily medications?
Why does one study suggest weekly doses are key, while another shows a single dose is effective?
Repeated Psilocybin Dosing Achieves 73% Response Rate in OCD: Results from March 2026 Clinical Trial
Overview
The March 2026 clinical trial demonstrated that repeated doses of psilocybin significantly reduce OCD symptoms, with 73.3% of participants responding to treatment and 40% achieving full remission. These benefits persisted at six months, and no serious adverse events were reported, highlighting a strong safety profile supported by careful screening and controlled settings. Psilocybin works by activating serotonin 5HT2A receptors, disrupting overactive brain networks linked to OCD, promoting neuroplasticity, and fostering psychological openness. Effective therapy relies on skilled psychological support and ethical therapist training. Despite promising results, regulatory restrictions and high treatment costs limit accessibility, underscoring the need for larger trials, economic analyses, and scalable care models.